TY - JOUR
T1 - Prediction system for risk of allograft loss in patients receiving kidney transplants
T2 - International derivation and validation study
AU - Loupy, Alexandre
AU - Aubert, Olivier
AU - Orandi, Babak J.
AU - Naesens, Maarten
AU - Bouatou, Yassine
AU - Raynaud, Marc
AU - Divard, Gillian
AU - Jackson, Annette M.
AU - Viglietti, Denis
AU - Giral, Magali
AU - Kamar, Nassim
AU - Thaunat, Olivier
AU - Morelon, Emmanuel
AU - Delahousse, Michel
AU - Kuypers, Dirk
AU - Hertig, Alexandre
AU - Rondeau, Eric
AU - Bailly, Elodie
AU - Eskandary, Farsad
AU - Böhmig, Georg
AU - Gupta, Gaurav
AU - Glotz, Denis
AU - Legendre, Christophe
AU - Montgomery, Robert A.
AU - Stegall, Mark D.
AU - Empana, Jean Philippe
AU - Jouven, Xavier
AU - Segev, Dorry L.
AU - Lefaucheur, Carmen
N1 - Funding Information:
Funding: INSERM–Action thématique incitative sur programme Avenir (ATIP-Avenir) provided financial support; OA received a grant from the Fondation Bettencourt Schueller; MN received grants from the Research Foundation, Flanders (FWO; IWT.150199), the Flanders Innovation and Entrepreneurship of the Flemish government (IWT.130758), and the Clinical Research Foundation of the University Hospitals Leuven.
Publisher Copyright:
© Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to.
PY - 2019/9/17
Y1 - 2019/9/17
N2 - Objective To develop and validate an integrative system to predict long term kidney allograft failure. Design International cohort study. Setting Three cohorts including kidney transplant recipients from 10 academic medical centres from Europe and the United States. Participants Derivation cohort: 4000 consecutive kidney recipients prospectively recruited in four French centres between 2005 and 2014. Validation cohorts: 2129 kidney recipients from three centres in Europe and 1428 from three centres in North America, recruited between 2002 and 2014. Additional validation in three randomised controlled trials (NCT01079143, EudraCT 2007-003213-13, and NCT01873157). Main outcome measure Allograft failure (return to dialysis or pre-emptive retransplantation). 32 candidate prognostic factors for kidney allograft survival were assessed. Results Among the 7557 kidney transplant recipients included, 1067 (14.1%) allografts failed after a median post-transplant follow-up time of 7.12 (interquartile range 3.51-8.77) years. In the derivation cohort, eight functional, histological, and immunological prognostic factors were independently associated with allograft failure and were then combined into a risk prediction score (iBox). This score showed accurate calibration and discrimination (C index 0.81, 95% confidence interval 0.79 to 0.83). The performance of the iBox was also confirmed in the validation cohorts from Europe (C index 0.81, 0.78 to 0.84) and the US (0.80, 0.76 to 0.84). The iBox system showed accuracy when assessed at different times of evaluation post-transplant, was validated in different clinical scenarios including type of immunosuppressive regimen used and response to rejection therapy, and outperformed previous risk prediction scores as well as a risk score based solely on functional parameters including estimated glomerular filtration rate and proteinuria. Finally, the accuracy of the iBox risk score in predicting long term allograft loss was confirmed in the three randomised controlled trials. Conclusion An integrative, accurate, and readily implementable risk prediction score for kidney allograft failure has been developed, which shows generalisability across centres worldwide and common clinical scenarios. The iBox risk prediction score may help to guide monitoring of patients and further improve the design and development of a valid and early surrogate endpoint for clinical trials. Trial registration Clinicaltrials.gov NCT03474003.
AB - Objective To develop and validate an integrative system to predict long term kidney allograft failure. Design International cohort study. Setting Three cohorts including kidney transplant recipients from 10 academic medical centres from Europe and the United States. Participants Derivation cohort: 4000 consecutive kidney recipients prospectively recruited in four French centres between 2005 and 2014. Validation cohorts: 2129 kidney recipients from three centres in Europe and 1428 from three centres in North America, recruited between 2002 and 2014. Additional validation in three randomised controlled trials (NCT01079143, EudraCT 2007-003213-13, and NCT01873157). Main outcome measure Allograft failure (return to dialysis or pre-emptive retransplantation). 32 candidate prognostic factors for kidney allograft survival were assessed. Results Among the 7557 kidney transplant recipients included, 1067 (14.1%) allografts failed after a median post-transplant follow-up time of 7.12 (interquartile range 3.51-8.77) years. In the derivation cohort, eight functional, histological, and immunological prognostic factors were independently associated with allograft failure and were then combined into a risk prediction score (iBox). This score showed accurate calibration and discrimination (C index 0.81, 95% confidence interval 0.79 to 0.83). The performance of the iBox was also confirmed in the validation cohorts from Europe (C index 0.81, 0.78 to 0.84) and the US (0.80, 0.76 to 0.84). The iBox system showed accuracy when assessed at different times of evaluation post-transplant, was validated in different clinical scenarios including type of immunosuppressive regimen used and response to rejection therapy, and outperformed previous risk prediction scores as well as a risk score based solely on functional parameters including estimated glomerular filtration rate and proteinuria. Finally, the accuracy of the iBox risk score in predicting long term allograft loss was confirmed in the three randomised controlled trials. Conclusion An integrative, accurate, and readily implementable risk prediction score for kidney allograft failure has been developed, which shows generalisability across centres worldwide and common clinical scenarios. The iBox risk prediction score may help to guide monitoring of patients and further improve the design and development of a valid and early surrogate endpoint for clinical trials. Trial registration Clinicaltrials.gov NCT03474003.
UR - http://www.scopus.com/inward/record.url?scp=85072273901&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072273901&partnerID=8YFLogxK
U2 - 10.1136/bmj.l4923
DO - 10.1136/bmj.l4923
M3 - Article
C2 - 31530561
AN - SCOPUS:85072273901
SN - 0959-8146
VL - 366
JO - The BMJ
JF - The BMJ
M1 - l4923
ER -